Intracranial atherosclerotic stenosis (ICAS) is one of the most frequent causes of stroke
worldwide and confers one of the greatest risks of recurrent stroke compared with other …

Background and Purpose—The purpose of these guidelines is to provide an up-to-date
comprehensive set of recommendations in a single document for clinicians caring for adult …

Background Comparisons between ticagrelor and clopidogrel for the secondary prevention
of stroke in CYP2C19 loss-of-function carriers have not been extensively performed …

Background The benefit of combined treatment with intravenous thrombolysis before
endovascular thrombectomy in patients with acute ischaemic stroke caused by large vessel …

Background Combination antiplatelet therapy with clopidogrel and aspirin may reduce the
rate of recurrent stroke during the first 3 months after a minor ischemic stroke or transient …

The 2020 update of the Canadian Stroke Best Practice Recommendations (CSBPR) for the
Secondary Prevention of Stroke includes current evidence-based recommendations and …

The management of patients with stroke is often multidisciplinary, involving various
specialties and healthcare professionals. Given the common shared risk factors for stroke …

Large vessel occlusion stroke due to underlying intracranial atherosclerotic disease (ICAD-
LVO) is prevalent in 10 to 30% of LVOs depending on patient factors such as vascular risk …

Background: The association of genetic polymorphisms and clopidogrel efficacy in patients
with ischemic stroke or transient ischemic attack (TIA) remains controversial. We performed …

Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …